This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies and how to manage them see our Privacy Policy.

b_banpc-880.png
b_banpc.png

ABOUT US

Hope Medicine Inc.

Hope Medicine (HopeMed) is a science-driven, patient-centric, clinical-stage biotech company with research and development bases in major innovation hubs in China. The company was established on the foundation of deep understanding of disease biology and translational medicine, and decades of scientific research in the laboratory of the founder, Professor Rui-Ping Xiao, at Peking University. With a management team of highly accomplished industry veterans combining entrepreneurship and global pharma experience, HopeMed is committed to the discovery, development, and commercialization of innovative, safe, effective, affordable medicines for large, underserved patient populations. Strategically, we are building a robust pipeline in the field of endocrine, cardiovascular and metabolic diseases, with a special focus on women’s health, through internal R&D capabilities, access to external technology platforms to enable a variety of molecular modalities, as well as in-license of complementary and differentiated assets to address unmet medical needs.

Leveraging our extensive KOL network of highly influential academic and clinical experts, we initiated our clinical program following a worldwide exclusive license agreement with Bayer AG on the development and commercialization of a potential first-in-class human antibody (HMI-115) targeting the prolactin receptor for the treatment of endometriosis, androgenic alopecia, and other diseases with dysregulated prolactin signaling.

Our vision is to lead the field of prolactin research and fully explore, develop and commercialize the potential clinical use of HMI-115. Together with a strong internal portfolio, we will strive to become a fully integrated biopharmaceutical company that develops medicines with breakthrough potential to improve the quality of life for patients around the world.

ab.jpg

Leadership Team

Rui-Ping-Xiao.jpg

Rui-Ping Xiao

M.D., Ph.D.

Founder, Chairperson of the Board

MORE

Henri-Nico-Doods.jpg

Henri Nico Doods

Ph.D.

CEO, CSO

MORE

Sam-Lou.jpg

Sam Lou

MBA

Co-Founder, President, COO

MORE

tupian1.png

Cindy Li

M.D.

CMO

MORE

DamianTu-617.jpg

Damian Tu

Ph.D.

Head of Pharmaceutical R&D

MORE

weibiaoti-4.jpg

Jane Wang

DBA, MBA

CHRO

MORE

Corporate History

2022 Q2

2022 Q1

2021 Q4

2021 Q2

2020 Q4

2020 Q2

2020 Q1

2019 Q2

2019 Q1

2018

AGA trial started in Australia

Safe-to-proceed for HMI-115 in the indication of Androgenetic Alopecia from FDA

Phase II Endometriosis Trail started in the U.S.

Round B closed, led by QiMing Venture Partners and Grand Flight

First HMI-115 Safe-to-proceed from FDA (Endometriosis)

Dr. Henri Doods joined the team

HMI-115 clinical trial material released

Clinical and RA team on-board HMI-115  drug product and GMP run at WXB, for MRCT phase 2 trials

HopeMed-PKU Joint research center

HMI-115 Clinical GMP lot released

Bayer licensed global rights of HMI-115 to Hope Medicine

Preclinical Team Built

100M Investment from Ennovation Venture

Round A closed by TrustBridge $10 MM

PKU and Nanjing Jiangbei Jiangbei New Area reached a strategic cooperation agreement

Hope Medicine registered

Follow Us

g_img1.png

Top